PT  - JOURNAL ARTICLE
AU  - Johari, Yusuf B.
AU  - Jaffé, Stephen R.P.
AU  - Scarrott, Joseph M.
AU  - Johnson, Abayomi O.
AU  - Mozzanino, Théo
AU  - Pohle, Thilo H.
AU  - Maisuria, Sheetal
AU  - Bhayat-Cammack, Amina
AU  - Brown, Adam J.
AU  - Tee, Kang Lan
AU  - Jackson, Philip J.
AU  - Wong, Tuck Seng
AU  - Dickman, Mark J.
AU  - Sargur, Ravishankar
AU  - James, David C.
TI  - Production of Trimeric SARS-CoV-2 Spike Protein by CHO Cells for Serological COVID-19 Testing
AID  - 10.1101/2020.08.07.20169441
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.07.20169441
4099  - http://medrxiv.org/content/early/2020/08/13/2020.08.07.20169441.short
4100  - http://medrxiv.org/content/early/2020/08/13/2020.08.07.20169441.full
AB  - We describe scalable and cost-efficient production of full length, His-tagged SARS-CoV-2 spike glycoprotein trimer by CHO cells that can be used to detect SARS-CoV-2 antibodies in patient sera at high specificity and sensitivity. Transient production of spike in both HEK and CHO cells mediated by PEI was increased significantly (up to 10.9-fold) by a reduction in culture temperature to 32°C to permit extended duration cultures. Based on these data GS-CHO pools stably producing spike trimer under the control of a strong synthetic promoter were cultured in hypothermic conditions with combinations of bioactive small molecules to increase yield of purified spike product 4.9-fold to 53 mg/L. Purification of recombinant spike by Nichelate affinity chromatography initially yielded a variety of co-eluting protein impurities identified as host cell derived by mass spectrometry, which were separated from spike trimer using a modified imidazole gradient elution. Purified CHO spike trimer antigen was used in ELISA format to detect IgG antibodies against SARS-CoV-2 in sera from patient cohorts previously tested for viral infection by PCR, including those who had displayed COVID-19 symptoms. The antibody assay, validated to ISO 15189 Medical Laboratories standards, exhibited a specificity of 100% and sensitivity of 92.3%. Our data show that CHO cells are a suitable host for the production of larger quantities of recombinant SARS-CoV-2 trimer which can be used as antigen for mass serological testing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSheffield Teaching Hospitals NHS Foundation Trust, UK.MJD acknowledges support from the Biotechnology and Biological SciencesResearch Council UK (BBSRC) (BB/M012166/1)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Local R&D and ethics committees advised ethics approval was not required. The interpretation was this is governed under the Development, validation and verification of new assays and the UKAS Laboratory accreditation quality governance framework. The name of the entity is Sheffield Teaching Hospital Research and Innovation Office.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data discussed in the text is submitted as supplementary information.